HW
VRTX icon

Hancock Whitney’s Vertex Pharmaceuticals VRTX Stock Holding History

Hancock Whitney’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$574K Buy
1,341
+15
+1% +$6.99K 0.01% 538
2025
Q4 		$601K Sell
1,326
-13
-1% -$5.6K 0.01% 516
2025
Q3 		$524K Sell
1,339
-23
-2% -$9.61K 0.01% 556
2025
Q2 		$606K Buy
1,362
+19
+1% +$8.76K 0.01% 523
2025
Q1 		$651K Sell
1,343
-184
-12% -$85.7K 0.02% 391
2024
Q4 		$615K Sell
1,527
-1,181
-44% -$547K 0.02% 399
2024
Q3 		$1.26M Sell
2,708
-79
-3% -$37.9K 0.04% 276
2024
Q2 		$1.31M Sell
2,787
-5
-0.2% -$2.17K 0.04% 256
2024
Q1 		$1.17M Buy
2,792
+101
+4% +$42.7K 0.04% 278
2023
Q4 		$1.09M Sell
2,691
-93
-3% -$34.4K 0.04% 297
2023
Q3 		$968K Buy
2,784
+33
+1% +$11.5K 0.04% 306
2023
Q2 		$968K Buy
2,751
+208
+8% +$70.1K 0.04% 318
2023
Q1 		$801K Buy
2,543
+725
+40% +$217K 0.03% 336
2022
Q4 		$525K Buy
1,818
+2
+0.1% +$610 0.02% 423
2022
Q3 		$526K Buy
1,816
+18
+1% +$5.18K 0.02% 406
2022
Q2 		$507K Sell
1,798
-290
-14% -$77.6K 0.02% 418
2022
Q1 		$545K Buy
2,088
+101
+5% +$24K 0.02% 440
2021
Q4 		$436K Buy
1,987
+24
+1% +$4.67K 0.01% 509
2021
Q3 		$356K Buy
1,963
+24
+1% +$4.69K 0.01% 542
2021
Q2 		$391K Sell
1,939
-113
-6% -$23.6K 0.01% 617
2021
Q1 		$441K Sell
2,052
-1,753
-46% -$385K 0.02% 576
2020
Q4 		$899K Sell
3,805
-35
-0.9% -$8.03K 0.03% 402
2020
Q3 		$1.04M Sell
3,840
-440
-10% -$121K 0.04% 360
2020
Q2 		$1.24M Sell
4,280
-55
-1% -$14.9K 0.05% 333
2020
Q1 		$1.03M Buy
4,335
+135
+3% +$31K 0.04% 359
2019
Q4 		$920K Sell
4,200
-201
-5% -$40.7K 0.03% 455
2019
Q3 		$746K Sell
4,401
-134
-3% -$23.7K 0.02% 499
2019
Q2 		$832K Sell
4,535
-51
-1% -$8.92K 0.03% 500
2019
Q1 		$844K Buy
4,586
+35
+0.8% +$6.46K 0.03% 506
2018
Q4 		$754K Buy
4,551
+1,935
+74% +$335K 0.03% 475
2018
Q3 		$504K Buy
+2,616
New +$466K 0.01% 640

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hancock Whitney's VRTX Position: Q1 2026 in Review

Hancock Whitney increased its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q1 2026, buying an estimated $6.99K and bringing the position to 1,341 shares worth $574K. The position accounts for 0.01% of the portfolio, ranked #538.

Hancock Whitney first reported a position in VRTX in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.31M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Hancock Whitney held 1,341 shares of Vertex Pharmaceuticals worth $574K as of Q1 2026.
  • Hancock Whitney bought 15 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.99K.
  • Vertex Pharmaceuticals made up 0.01% of Hancock Whitney's portfolio in Q1 2026, its #538 holding.
  • Hancock Whitney first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Hancock Whitney's Vertex Pharmaceuticals position peaked at $1.31M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Hancock Whitney's 13F filing for Q1 2026, filed 15 May 2026.